The results showed that tumor mutation frequency of high-risk group was higher (Supplementary Figure S3A), including KRAS (64%), TP53 (66%), SMAD4 (21%), CDKN2A (17%) and TTN (10%). This evidence concerns the gene KRAS and neoplasm.